Tesamorelin is a 44-amino-acid synthetic analog of GHRH (growth hormone releasing hormone) and the only FDA-approved peptide specifically for visceral fat reduction. Originally developed for HIV-associated lipodystrophy, tesamorelin reduces visceral adipose tissue by 15 to 18% in clinical trials with measurable improvements in waist circumference, triglycerides, and insulin sensitivity. This guide covers the tesamorelin benefits backed by trial data, dosing, side effects, and how it compares to other GH peptides for fat loss.
For users with stubborn abdominal fat that has not responded to caloric deficit alone, tesamorelin is the most evidence-based option in the peptide toolkit. The FDA approval (granted in 2010 as Egrifta) provides a level of safety and efficacy data unmatched in the peptide category.
What Is Tesamorelin?
Tesamorelin (brand name Egrifta) is a stabilized GHRH analog. It binds to the GHRH receptor on the pituitary gland and triggers pulsatile growth hormone release. Unlike CJC-1295, tesamorelin’s modifications give it a longer half-life and more pronounced effect on visceral fat specifically.
The mechanism of action:
- Tesamorelin binds GHRH receptors on pituitary somatotrophs.
- Pituitary releases pulsatile GH (preserves natural rhythm, unlike synthetic hGH).
- GH triggers IGF-1 production in the liver.
- GH and IGF-1 activate hormone-sensitive lipase, with preferential effect on visceral fat depots.
- Stored visceral triglycerides are mobilized for fuel.
The visceral specificity is the unique part. Most fat-loss peptides work systemically; tesamorelin produces measurably greater effects on visceral fat than on subcutaneous fat in clinical imaging studies.
Tesamorelin Trial Data: 15 to 18% Visceral Fat Reduction
Two pivotal phase 3 trials in HIV-associated lipodystrophy (Falutz et al., NEJM 2007; and a 26-week extension) demonstrated:
| Outcome (vs placebo) | 26-week change |
|---|---|
| Visceral adipose tissue (CT measured) | -15.2% to -18% |
| Trunk fat | -3.2 kg |
| Waist circumference | -2.7 cm |
| Triglycerides | -50 mg/dL |
| Total cholesterol | -19 mg/dL |
| IGF-1 levels | +157% (within physiological range) |
Subsequent studies in non-HIV populations with abdominal obesity showed similar results: 15 to 17% visceral fat reduction over 12 to 24 weeks of dosing. The effect size is robust across populations.
Tesamorelin Benefits Beyond Fat Loss
Trial data and clinical use have identified secondary benefits:
- Improved liver function: trials in NAFLD (non-alcoholic fatty liver disease) showed reduced liver fat and improved liver enzymes.
- Cognitive function: a NIH-funded trial on cognitive aging showed improved executive function and memory in older adults treated with tesamorelin.
- Triglyceride reduction: the lipid profile improvements are clinically meaningful, particularly for users with metabolic syndrome.
- Improved insulin sensitivity: in some studies, paradoxically, despite GH’s typical insulin-counterregulatory effect.
The cognitive benefit is particularly interesting and is being investigated as a potential off-label use for age-related cognitive decline.
Tesamorelin Dosage Protocol
The standard FDA-approved protocol:
- Dose: 1 mg subcutaneous, daily
- Timing: morning, ideally before breakfast (the GHRH receptor is most responsive during the natural morning cortisol peak)
- Cycle length: 12 to 26 weeks for visceral fat reduction; can be extended for users tolerating well
- Site rotation: rotate abdominal injection sites to avoid local lipoatrophy
Some research-use protocols use 2 mg daily for the first 4 to 8 weeks, then drop to 1 mg maintenance. The clinical evidence does not strongly support the higher dose; 1 mg captures most of the benefit.
Reconstitution
Research-grade tesamorelin ships as 5 mg or 10 mg lyophilized vials.
For 5 mg vial: add 2.5 mL bacteriostatic water → 2 mg/mL → 1 mg dose = 0.5 mL (50 units on insulin syringe).
For 10 mg vial: add 5 mL bacteriostatic water → 2 mg/mL → 1 mg dose = 0.5 mL.
Refrigerate after reconstitution; stable 30 days. Tesamorelin is sensitive to temperature; never leave at room temperature for more than a few hours.
Side Effects of Tesamorelin
From the FDA trials and post-marketing surveillance:
- Common: injection site reactions (redness, itching, lumps), arthralgia (joint pain), fluid retention (peripheral edema), peripheral paresthesia (tingling).
- Less common: rash, pruritus, myalgia.
- Rare but serious: glucose intolerance and diabetes onset (GH effect), hypersensitivity reactions.
The fluid retention is dose-dependent and usually resolves after 4 to 6 weeks of continued use. Users with carpal tunnel risk should monitor for hand numbness.
Tesamorelin vs Other GH Peptides for Fat Loss
| Peptide | Visceral fat focus | Muscle gain | Cost (research grade) |
|---|---|---|---|
| Tesamorelin | Strong, FDA-validated | Modest | $$$$ |
| CJC-1295 + Ipamorelin | Moderate | Strong | $$ |
| AOD-9604 | Weak (general fat) | None | $$ |
| Hexarelin | Moderate | Moderate | $$ |
Tesamorelin is the right choice when visceral fat specifically is the goal. CJC + Ipamorelin is the better choice for general body recomposition.
Stacking Tesamorelin With Other Peptides
Common stack additions:
- + Ipamorelin (200 to 250 mcg pre-bed): amplifies GH pulse via the GHSR pathway. Tesamorelin morning, Ipamorelin evening. Avoids receptor competition by separating timing.
- + BPC-157 (250 mcg daily): gut and recovery support. Useful if you have any GI issues that make daily injections uncomfortable.
- + Tirzepatide or Semaglutide (weekly): dual approach for users with significant overall obesity plus visceral fat. The GLP-1 reduces general intake; tesamorelin specifically targets the visceral depot.
Avoid stacking with CJC-1295 (no DAC) at the same time of day. Both compete for the GHRH receptor; combining them does not produce additive effect.
Common Tesamorelin Mistakes
- Skipping doses inconsistently: tesamorelin works through sustained signaling. Missing 2 to 3 doses per week reduces results significantly.
- Stopping at 8 weeks because progress feels slow: visceral fat reduction is gradual. Most measurable effects occur between weeks 12 and 24.
- Inadequate protein intake: GH peptides plus low protein produce poor lean mass preservation. Target 1.6 to 2.0 g/kg.
- Combining with high-fat meals at injection time: fatty meals near injection blunt GH release. Inject fasted, ideally first thing in the morning.
- Using DAC-modified versions: tesamorelin is itself a stabilized form. Daily dosing of unmodified tesamorelin is the proven protocol; weekly DAC versions are not equivalent.
Who Should Avoid Tesamorelin
- Users with active malignancy (GH and IGF-1 elevation may accelerate tumor growth)
- Users with diabetic retinopathy (GH effects can worsen)
- Pregnant or breastfeeding women
- Users with hypersensitivity to tesamorelin or mannitol (a common excipient)
- Users with severe glucose intolerance who are not actively monitoring blood sugar
Frequently Asked Questions
How long until I see tesamorelin results?
Waist circumference changes are typically visible by week 8. Measurable visceral fat reduction (CT or MRI) requires 12 weeks. Maximum effect occurs at 24 to 26 weeks.
Will I keep the visceral fat loss after stopping?
Without lifestyle changes, regression is the rule. Trials show partial regain within 24 to 26 weeks of stopping. Continued exercise, protein intake, and metabolic management are necessary to maintain results.
Can tesamorelin be used for general weight loss?
It can but it is not optimized for that. For general weight loss, GLP-1 class peptides are more effective. Tesamorelin shines specifically for visceral fat depot reduction with secondary benefits to lipids and liver function.
Is tesamorelin safe long-term?
The FDA approved indefinite use for the lipodystrophy indication, suggesting long-term safety is acceptable in monitored populations. For research use, most users limit to 26-week cycles with breaks of 8 to 12 weeks before re-cycling.
Can I use tesamorelin with insulin or diabetes medications?
Tesamorelin can elevate fasting glucose and worsen insulin sensitivity in some users. Diabetic patients should monitor blood glucose closely and adjust diabetes medications under medical supervision.
Where can I get research-grade tesamorelin?
For research-grade tesamorelin in Indonesia and Southeast Asia, see our pricelist. Order directly via WhatsApp with temperature-controlled delivery.
This article is for informational and research-use purposes only. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Off-label use should be discussed with a qualified medical professional.